<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35390511</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-2030</ISSN><JournalIssue CitedMedium="Internet"><Volume>116</Volume><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Contemporary clinical trials</Title><ISOAbbreviation>Contemp Clin Trials</ISOAbbreviation></Journal><ArticleTitle>The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design.</ArticleTitle><Pagination><StartPage>106755</StartPage><MedlinePgn>106755</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cct.2022.106755</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1551-7144(22)00081-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">COVID-19, a disease caused by infection with the SARS-CoV-2 virus, is asymptomatic or mildly symptomatic in most cases. Some patients, usually burdened with risk factors develop acute respiratory failure and other organ dysfunction. In such cases, the mortality rate is very high despite the use of intensive therapy. Amantadine has complex activity including antiviral, antiinflammatory and dopaminergic effects. This clinical trial will assess the efficacy and safety of amantadine in the prevention of COVID-19 progression toward acute respiratory failure and neurological complications.</AbstractText><AbstractText Label="METHODS AND RESULTS">The trial will enroll 200 patients who are positive for SARS-CoV-2 infection and have one or more risk factors for worsening the disease. These patients will be included as hospitalized or ambulatory subjects for early treatment of illness. The recruitment will take place in 8 centers covering different regions of Poland. For 14&#xa0;days they will be given either 200&#xa0;mg of amantadine a day or placebo. Our hypothesis is a considerable reduction in the number of patients with progression toward respiratory insufficiency or neurological complications thanks to the treatment of amantadine.</AbstractText><AbstractText Label="CONCLUSIONS">Demonstrating the efficacy and safety of amantadine treatment in improving the clinical condition of patients diagnosed with COVID-19 is of great importance in combating the effects of the pandemic. It has potential to influence on the severity and course of neurological complications, which are very common and persist long after the infection as long-COVID syndrome.</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION">www.</AbstractText><AbstractText Label="CLINICALTRIALS">gov identification no. NCT04854759; Eudra CT number: 2021-001144-98 (dated 27 February 2021).</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rejdak</LastName><ForeName>Konrad</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Lublin, Lublin, Poland. Electronic address: k.rejdak@umlub.pl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiedor</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of General and Transplantation Surgery, Medical University of Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonek</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Clinical Neuroimmunology, Regional Specialist Hospital, Grudziadz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goch</LastName><ForeName>Aleksander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Clinical Neuroimmunology, Regional Specialist Hospital, Grudziadz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gala-B&#x142;&#x105;dzi&#x144;ska</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Rzesz&#xf3;w, Rzesz&#xf3;w, Poland; St' Queen Jadwiga Clinical District Hospital No. 2, Rzesz&#xf3;w, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Che&#x142;stowski</LastName><ForeName>Waldemar</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Regional Hospital SPZZOZ in Wyszk&#x3cc;w, Wyszk&#x3cc;w, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x141;ukasiak</LastName><ForeName>Jacek</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Regional Hospital SPZZOZ in Wyszk&#x3cc;w, Wyszk&#x3cc;w, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiciak</LastName><ForeName>S&#x142;awomir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Independent Voivodeship Hospital "Jana Bo&#x17c;ego" in Lublin, Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#x105;browski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Independent Voivodeship Hospital "Jana Bo&#x17c;ego" in Lublin, Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dec</LastName><ForeName>Mateusz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>SPZOZ Kalwaria Zebrzydowska, Kalwaria Zebrzydowska, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kr&#xf3;l</LastName><ForeName>Zbigniew J</ForeName><Initials>ZJ</Initials><AffiliationInfo><Affiliation>Central Clinical Hospital of the Ministry of the Interior and Administration, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papu&#x107;</LastName><ForeName>Ewa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Lublin, Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zasybska</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Lublin, Lublin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segiet</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Chair and Department of Experimental and Clinical Physiology, Medical University of Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grieb</LastName><ForeName>Pawe&#x142;</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Experimental Pharmacology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04854759</AccessionNumber></AccessionNumberList></DataBank><DataBank><DataBankName>EudraCT</DataBankName><AccessionNumberList><AccessionNumber>2021&#x2013;001144-98</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Contemp Clin Trials</MedlineTA><NlmUniqueID>101242342</NlmUniqueID><ISSNLinking>1551-7144</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>BF4C9Z1J53</RegistryNumber><NameOfSubstance UI="D000547">Amantadine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000547" MajorTopicYN="N">Amantadine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="Y">Respiratory Insufficiency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amantadine</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Neurological complications</Keyword><Keyword MajorTopicYN="N">Outcome</Keyword><Keyword MajorTopicYN="N">Protocol</Keyword><Keyword MajorTopicYN="N">Trial</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>7</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35390511</ArticleId><ArticleId IdType="pmc">PMC8978450</ArticleId><ArticleId IdType="doi">10.1016/j.cct.2022.106755</ArticleId><ArticleId IdType="pii">S1551-7144(22)00081-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Buitrago-Garcia D., Egli-Gany D., Counotte M.J., et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 2020;17:e1003346. Sep 22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7508369</ArticleId><ArticleId IdType="pubmed">32960881</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai B., Shukla A., Dwivedi L.K. Incubation period for COVID-19: a systematic review and meta-analysis. Z Gesundh Wiss. 2021:1&#x2013;8. Feb 23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7901514</ArticleId><ArticleId IdType="pubmed">33643779</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi H.K., Mehra M.R. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J. Heart Lung Transplant. 2020;39:405&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118652</ArticleId><ArticleId IdType="pubmed">32362390</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim P.S., Read S.W., Fauci A.S. Therapy for early COVID-19: a critical need. JAMA. 2020;324:2149&#x2013;2150.</Citation><ArticleIdList><ArticleId IdType="pubmed">33175121</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante C.T., Buse J., Tamaritz L., et al. Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. J. Med. Virol. 2021;93:4273&#x2013;4279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013587</ArticleId><ArticleId IdType="pubmed">33580540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lally M.A., Tsoukas P., Halladay C.W., et al. Metformin is associated with decreased 30-day mortality among nursing home residents infected with SARS-CoV2. J. Am. Med. Dir. Assoc. 2021;22:193&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7586924</ArticleId><ArticleId IdType="pubmed">33232684</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. Eur. Arch. Psychiatry Clin. Neurosci. 2021;271:249&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7785036</ArticleId><ArticleId IdType="pubmed">33403480</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenze E.J., Mattar C., Zorumski C.F., et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324:2292&#x2013;2300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7662481</ArticleId><ArticleId IdType="pubmed">33180097</ArticleId></ArticleIdList></Reference><Reference><Citation>Seftel D., Boulware D.R. Prospective cohort of fluvoxamine for early treatment of Coronavirus Disease 19. Open Forum Infect Dis. 2021;8:ofab050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7888564</ArticleId><ArticleId IdType="pubmed">33623808</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhidayasiri R., Virameteekul S., Kim J.M., et al. COVID-19: an early review of its global impact and considerations for Parkinson&#x2019;s disease patient care. J Mov Disord. 2020;13:105&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280938</ArticleId><ArticleId IdType="pubmed">32344993</ArticleId></ArticleIdList></Reference><Reference><Citation>Rejdak K., Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord. 2020;42:102163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190496</ArticleId><ArticleId IdType="pubmed">32388458</ArticleId></ArticleIdList></Reference><Reference><Citation>Grieb P., Rejdak K. Are central nervous system drugs displaying anti-inflammatory activity suitable for early treatment of COVID-19? Folia Neuropathol. 2021;59(2):113&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">34284539</ArticleId></ArticleIdList></Reference><Reference><Citation>Danysz W., Dekundy A., Scheschonka A., et al. Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials. J. Neural Transm. (Vienna) 2021;128:127&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7901515</ArticleId><ArticleId IdType="pubmed">33624170</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain M., Galvin H.D., Haw T.Y., et al. Drug resistance in influenza a virus: the epidemiology and management. Infect Drug Resist. 2017;10:121&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404498</ArticleId><ArticleId IdType="pubmed">28458567</ArticleId></ArticleIdList></Reference><Reference><Citation>Paik J., Keam S.J. Amantadine extended-release (GOCOVRITM): a review in levodopa-induced dyskinesia in Parkinson&#x2019;s disease. CNS Drugs. 2018;32:797&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">30088203</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez D.Q., Espiritu A.I., Jamora R.D.G. Efficacy and safety of amantadine for the treatment of fatigue in multiple sclerosis: a systematic review and meta-analysis. Neurodegener Dis Manag. 2020;10:383&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">33012266</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietrich D.E., Bode L., Spannhuth C.W., et al. Antiviral treatment perspective against Borna disease virus 1 infection in major depression: a double-blind placebo-controlled randomized clinical trial. BMC Pharmacol. Toxicol. 2020;21:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7027224</ArticleId><ArticleId IdType="pubmed">32066504</ArticleId></ArticleIdList></Reference><Reference><Citation>Jim&#xe9;nez-Jim&#xe9;nez F.J., Alonso-Navarro H., Garc&#xed;a-Mart&#xed;n E., et al. Anti-inflammatory effects of amantadine and Memantine: possible therapeutics for the treatment of Covid-19? J Pers Med. 2020;10:217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7712421</ArticleId><ArticleId IdType="pubmed">33182350</ArticleId></ArticleIdList></Reference><Reference><Citation>Cort&#xe9;s-Borra A., Aranda-Abreu G.E. Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2. Pharmacol. Rep. 2021:1&#x2013;4. doi: 10.1007/s43440-021-00231-5. Feb 18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-021-00231-5</ArticleId><ArticleId IdType="pmc">PMC7891470</ArticleId><ArticleId IdType="pubmed">33604795</ArticleId></ArticleIdList></Reference><Reference><Citation>Aranda-Abreu G.E., Aranda-Mart&#xed;nez J.D., Ara&#xfa;jo R. Use of amantadine in a patient with SARS-CoV-2. J. Med. Virol. 2021;93:110&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323182</ArticleId><ArticleId IdType="pubmed">32542661</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandala V.S., McKay M.J., Shcherbakov A.A., et al. Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers. Nat. Struct. Mol. Biol. 2020;27:1202&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7718435</ArticleId><ArticleId IdType="pubmed">33177698</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig A.M., Khaleeq A., Syeda H. Docking prediction of amantadine in the receptor binding domain of spike protein of SARS-CoV-2. ACS Pharmacol Transl Sci. 2020;3:1430&#x2013;1433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737314</ArticleId><ArticleId IdType="pubmed">33344913</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes C.P., Fernandes D.E., Casimiro F., et al. Cathepsin L in COVID-19: from pharmacological evidences to genetics. Front. Cell. Infect. Microbiol. 2020;10:589505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7753008</ArticleId><ArticleId IdType="pubmed">33364201</ArticleId></ArticleIdList></Reference><Reference><Citation>Smieszek S.P., Przychodzen B.P., Polymeropoulos M.H. Amantadine disrupts lysosomal gene expression: a hypothesis for COVID19 treatment. Int. J. Antimicrob. Agents. 2020;55:106004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7191300</ArticleId><ArticleId IdType="pubmed">32361028</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M.M., Yang W.L., Yang F.Y., et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021;6:134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7997800</ArticleId><ArticleId IdType="pubmed">33774649</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO COVID-19 Clinical management: living guidance. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected (accessed 21 August 2021)</Citation></Reference><Reference><Citation>Kaufmann S.H.E., Dorhoi A., Hotchkiss R.S. Host-directed therapies for bacterial and viral infections. Nat. Rev. Drug Discov. 2018;17:35&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097079</ArticleId><ArticleId IdType="pubmed">28935918</ArticleId></ArticleIdList></Reference><Reference><Citation>Grieb P., &#x15a;wi&#x105;tkiewicz M., Prus K., et al. Amantadine for COVID-19. J. Clin. Pharmacol. 2021;61:412&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">33350472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayres J.S. A metabolic handbook for the COVID-19 pandemic. Nat Metab. 2020;2:572&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7325641</ArticleId><ArticleId IdType="pubmed">32694793</ArticleId></ArticleIdList></Reference><Reference><Citation>Rejdak K., Grieb P. Fluvoxamine and amantadine: central nervous system acting drugs repositioned for COVID-19 as early intervention. Curr. Neuropharmacol. 2022;20:777&#x2013;778. doi: 10.2174/1570159X19666210729123734. 29 Jul.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X19666210729123734</ArticleId><ArticleId IdType="pmc">PMC9878960</ArticleId><ArticleId IdType="pubmed">34325642</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>